TRT gains on TikTok: hype vs. what the data shows

What did @calxshreds actually say?

The creator laid out a cost breakdown for what they openly call a PED cycle: testosterone at roughly 30 pounds per five weeks, primobolan at 60 pounds per five weeks, and blood work at 59 pounds every three months. The headline message was actually pretty reasonable: "if the answer is no, but you can afford the PEDs then you can't afford the PEDs." That framing, putting health monitoring costs before substance costs, is not what you typically see in gym-bro TRT content.

To be clear, this is not someone discussing prescribed testosterone replacement therapy for hypogonadism. This is someone describing a self-administered anabolic steroid stack. Primobolan (methenolone) is a Schedule III controlled substance in the UK and the US, not a regulated hormone therapy. Calling it "not too bad" financially glosses over the legal and clinical reality of what's being described.

Does the science back this up?

The advice to get blood work is solid. The cost figures are too low to reflect adequate monitoring. Three months between full panels is insufficient when running exogenous androgens, and 59 pounds likely does not cover everything that matters.

The research on anabolic steroid monitoring is unambiguous: hematocrit, lipid panels, liver enzymes, and cardiovascular markers need tracking. Baggish et al. (2017, Circulation) found that long-term anabolic steroid users had significantly impaired left ventricular function compared to non-users, with changes detectable even in otherwise healthy men. A basic blood panel at 59 pounds every three months would not catch early cardiac remodeling. Evans (2004, British Journal of Sports Medicine) documented that most AAS-related harms, including dyslipidemia and hepatotoxicity, develop silently and require proactive, frequent testing, not quarterly checks. Running testosterone and primobolan together without monitoring LH, FSH, estradiol, and SHBG is flying largely blind.

What did they get wrong (or right)?

Credit where it is due: the creator is right that blood work is not optional if you are using performance-enhancing drugs. That message, said plainly to an audience that may be tempted to skip it, has real value.

What they got wrong is scope. Quarterly blood work at 59 pounds is not a safety net, it is a suggestion of one. Rahnema et al. (2014, Fertility and Sterility) documented that exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis rapidly and sometimes irreversibly. A panel every 90 days will miss the early signs of suppression, polycythemia progression, or lipid deterioration that can shift meaningfully week to week at the doses implied.

The creator also makes no mention of estrogen management, which is standard even in supervised TRT protocols. Running a testosterone-based stack without tracking estradiol and aromatase activity is a meaningful omission that could mislead a less experienced viewer into thinking cost and blood work frequency are the only variables that matter.

• Blood work advice: correct in principle, inadequate in scope
• No mention of estradiol, LH, FSH, or cardiac markers
• Quarterly testing is below the standard of care for exogenous androgen use
• Legal and regulatory context: entirely absent

What should you actually know?

If you are considering testosterone therapy, the right starting point is a physician who can diagnose hypogonadism, not a cost breakdown on TikTok. Supervised TRT in the UK is available through NHS or regulated private providers. In the US, telehealth platforms can evaluate you properly.

If someone is already using anabolic steroids without medical supervision, the creator's core point still applies and then some. Blood work frequency for unsupervised AAS use in the sports medicine literature is generally recommended every four to six weeks during active use, not every three months. Christou et al. (2003, Journal of the American College of Cardiology) found AAS users had arterial dysfunction detectable within weeks of starting a cycle. Quarterly monitoring would miss that window entirely.

The "can you afford the blood work" framing is a good heuristic but it sets the floor too low. The actual question is whether you have access to a clinician who can interpret those results and intervene when something goes wrong, because a number on a lab report means nothing without clinical context.